Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8637315 | 0.94 | TSHR (0.67) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL7782013 | 0.92 | TSHR (0.70) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL7573260 | 0.92 | TSHR (0.70) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL11667209 | 0.92 | TSHR (0.70) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL6536159 | 0.92 | TSHR (0.70) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL9453921 | 0.92 | TSHR (0.70) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL253070 | 0.89 | — | — | |
| SCHEMBL153651 | 0.89 | TSHR (0.77) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL463195 | 0.89 | TSHR (0.70) | TSHRALDH1A1GAAEPHX2PKM | |
| SCHEMBL10834721 | 0.86 | TSHR (0.81) | TSHRALDH1A1GAAEPHX2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023120450-A1 | METHOD FOR PRODUCING ANTHRAQUINONES | 三菱重工業株式会社 | 2023-06-29 | — | — | WO | claimed |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2026-04-30 | — | — | US | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250213700-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4453003-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | Universität Wien (AT) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| WO-2023120450-A1 | METHOD FOR PRODUCING ANTHRAQUINONES | 三菱重工業株式会社 | 2023-06-29 | — | — | WO | disclosed |
| EP-1747207-A1 | FLUORESCENT METHOD AND COMPOUNDS TO MONITOR PROTEIN-LIPID BINDING | EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005113524-A1 | FLUORESCENT METHOD AND COMPOUNDS TO MONITOR PROTEIN-LIPID BINDING | Europäisches Laboratorium für Molekularbiologie (EMBL) (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20020042055-A1 | Alteration of hydrolase genes and screening of the resulting libraries for the ability to catalyze specific reactions | MAXYGEN, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001046476-A1 | ALTERATION OF HYDROLASE GENES AND SCREENING OF THE RESULTING LIBRARIES FOR THE ABILITY TO CATALYZE SPECIFIC REACTIONS | MAXYGEN, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6071899-A | Azetidinone derivatives for the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |
| US-5550215-A | FORMING POLYMER ON SUBSTRATE WITH A TETHER MOLECULE; CYCLIZATION; DEPROTECTING; DECYCLIZATION | AFFYMETRIX, INC. | 1996-08-27 | — | — | US | disclosed |
| WO-1996013484-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-09 | — | — | WO | disclosed |
| WO-1993010161-A1 | POLYMER REVERSAL ON SOLID SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-05-27 | — | — | WO | disclosed |
| US-4857520-A | Fused azepinone and azocinone derivatives, processes for their preparation, agents containing them and their use, and intermediates in their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213700-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DDT, ABCG2, CES2 | TSHR 2895/4885ALDH1A1 179/4885GAA 266/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | TSHR 54/4885ALDH1A1 409/4885GAA 3510/4885 |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | OXTR, CRH, TRHR | TSHR 32/4885ALDH1A1 3804/4885GAA 4595/4885 |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | BCR, PDCD1LG2, PRLHR | TSHR 862/4885ALDH1A1 1636/4885GAA 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.